IP Verse

Methods And Compositions For Delivering Mrna Coded Antibodies - EP2970456

The patent EP2970456 was granted to Shire Human Genetic Therapies on May 19, 2021. The application was originally filed on Mar 14, 2014 under application number EP14717945A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2970456

SHIRE HUMAN GENETIC THERAPIES
Application Number
EP14717945A
Filing Date
Mar 14, 2014
Status
Granted And Under Opposition
Apr 16, 2021
Grant Date
May 19, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

EIPFeb 21, 2022EIPADMISSIBLE
STRAWMANFeb 18, 2022MAIWALDADMISSIBLE
STRAWMANFeb 18, 2022VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE
WITHERS & ROGERSFeb 18, 2022TOMBLINGADMISSIBLE
GLAXOSMITHKLINEFeb 18, 2022HITCHCOCKWITHDRAWN

Patent Citations (52) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS19970835281-
DESCRIPTIONUS19980083294-
DESCRIPTIONUS4373071
DESCRIPTIONUS4401796
DESCRIPTIONUS4415732
DESCRIPTIONUS4458066
DESCRIPTIONUS4500707
DESCRIPTIONUS4668777
DESCRIPTIONUS4737323
DESCRIPTIONUS4897355
DESCRIPTIONUS4973679
DESCRIPTIONUS5047524
DESCRIPTIONUS5132418
DESCRIPTIONUS5153319
DESCRIPTIONUS5171678
DESCRIPTIONUS5262530
DESCRIPTIONUS5334761
DESCRIPTIONUS5700642
DESCRIPTIONUS5744335
DESCRIPTIONUS5885613
DESCRIPTIONWO2005121348
DESCRIPTIONWO2010042877
DESCRIPTIONWO2010053572
DESCRIPTIONWO2011068810
DESCRIPTIONWO2012170889
DESCRIPTIONWO2012170930
DESCRIPTIONWO2013063468
EXAMINATIONUS2012237975
EXAMINATIONWO2008083949
EXAMINATIONWO2012170930
INTERNATIONAL-SEARCH-REPORTWO2011068810
INTERNATIONAL-SEARCH-REPORTWO2012170930
OPPOSITIONUS2012237975
OPPOSITIONWO03048306
OPPOSITIONWO2006017325
OPPOSITIONWO2008083949
OPPOSITIONWO2009086558
OPPOSITIONWO2010054406
OPPOSITIONWO2011068810
OPPOSITIONWO2012006377
OPPOSITIONWO2012006378
OPPOSITIONWO2012045082
OPPOSITIONWO2012170889
OPPOSITIONWO2012170930
OPPOSITIONWO2013151666
OPPOSITIONWO2013185069
OPPOSITIONWO2014152774
OPPOSITIONWO2015061461
OTHEREP2970456
OTHERUS2012237975
OTHERWO2008083949
OTHERWO2012170930

Non-Patent Literature (NPL) Citations (101) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BEHR ET AL., PROC. NAT.'L ACAD. SCI., (1989), vol. 86, page 6982-
DESCRIPTION- BLOOMFIELD, ANN. REV. BIOPHYS. BIOENG., (1981), vol. 10, pages 421 - 150-
DESCRIPTION- FECHTER, P.; BROWNLEE, G.G., "Recognition of mRNA cap structures by viral and cellular proteins", J GEN. VIROLOGY, (2005), vol. 86, pages 1239 - 1249-
DESCRIPTION- FEIGNER ET AL., PROC. NAT'L ACAD. SCI., (1987), vol. 84, page 7413-
DESCRIPTION- GAO ET AL., BIOCHEM. BIOPHYS. RES. COMM., (1991), vol. 179, page 280-
DESCRIPTION- GILKESON ET AL., J. CLIN. INVEST., (1995), vol. 95, pages 1398 - 1402-
DESCRIPTION- GRAHAM ET AL., J. GEN VIROL., (1977), vol. 36, page 59-
DESCRIPTION- HEYES, J. ET AL., J CONTROLLED RELEASE, (2005), vol. 107, pages 276 - 287-
DESCRIPTION- HEYES, J.; PALMER, L.; BREMNER, K.; MACLACHLAN, I., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. CONTR. REL., (2005), vol. 107, pages 276 - 287-
DESCRIPTION- KLIBANOV ET AL., FEBS LETTERS, (1990), vol. 268, no. 1, pages 235 - 237-
DESCRIPTION- KOBER ET AL., BIOTECHNOL. BIOENG., (2012), vol. 110, pages 1164 - 73-
DESCRIPTION- LASIC ET AL., FEBS LETT., (1992), vol. 312, pages 255 - 258-
DESCRIPTION- LASIC, TRENDS BIOTECHNOL., (1998), vol. 16, pages 307 - 321-
DESCRIPTION- LOVE, K.T. ET AL., "Lipid-like materials for low-dose in vivo gene silencing", PNAS, (2010), vol. 107, pages 1864 - 1869-
DESCRIPTION- MATHER, BIOL. REPROD., (1980), vol. 23, pages 243 - 251-
DESCRIPTION- MATHER ET AL., ANNALS N.Y. ACAD. SCI., ( ), vol. 383, pages 44 - 68-
DESCRIPTION- MEYERS; MILLER, CABIOS, (1989), vol. 4, pages 11 - 17-
DESCRIPTION- MONTHEITH ET AL., ANTICANCER DRUG RES., (1997), vol. 12, no. 5, pages 421 - 432-
DESCRIPTION- MORRISSEY, DV. ET AL., NAT. BIOTECHNOL., (2005), vol. 23, no. 8, pages 1003 - 1007-
DESCRIPTION- Remington's Pharmaceutical Sciences, MACK PUBLISHING CO.-
DESCRIPTION- SEMPLE ET AL., NATURE BIOTECH., (2010), vol. 28, pages 172 - 176-
DESCRIPTION- SEMPLE, S.C. ET AL., "Rational Design of Cationic Lipids for siRNA Delivery", NATURE BIOTECH., (2010), vol. 28, pages 172 - 176-
DESCRIPTION- URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 4216-
DESCRIPTION- WOLF ET AL., BIOTECHNIQUES, (1997), vol. 23, page 139-
DESCRIPTION- YAMAMOTO Y ET AL., BIOCHEMISTRY, (1989), vol. 28, pages 2728 - 2732-
EXAMINATION- Ian MacLachlan, "Liposomal Formulatioons for Nucleic Acid Delivery", Ian MacLachlan, Stanley T. Crooke, Antisense Drug Technology, Boca Raton, Taylor and Francis Group, (20080101), pages 237 - 270, ISBN 0-8493-8796-5-
EXAMINATION- Michela Pisani, Giovanna Mobbili and Paolo Bruni, "Neutral Liposomes and DNA Transfection, Non-Viral Gene Therapy", Michela Pisani, Giovanna Mobbili and Paolo Bruni, Prof. Xubo Yuan, Non-Viral Gene Therapy, (20111107), doi:http://www.intechopen.com/books/non-viral-gene-therapy/neutral-liposomes-and-dna-transfection, ISBN 978-953-307-538-9-
EXAMINATION- MARTINON F ET AL, "INDUCTION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VIVO BY LIPOSOME-ENTRAPPED MRNA", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY VCH, WEINHEIM, (19930101), vol. 23, doi:10.1002/EJI.1830230749, ISSN 0014-2980, pages 1719 - 1722, XP000618955
EXAMINATION- PHILIPPOT J ET AL, "A very mild method allowing the encapsulation of very high amounts of macromolecules into very large (1000 nm) unilamellar liposomes", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, vol. 734, no. 2, doi:10.1016/0005-2736(83)90111-6, ISSN 0005-2736, (19831012), pages 137 - 143, (19831012), XP023509291
EXAMINATION- K. T. Love ET AL, "Lipid-like materials for low-dose, in vivo gene silencing", Proceedings of the National Academy of Sciences, (20100202), vol. 107, no. 5, doi:10.1073/pnas.0910603106, ISSN 0027-8424, pages 1864 - 1869, XP055077922
EXAMINATION- ANDREW J GEALL ET AL, "Nonviral delivery of self-amplifying RNA vaccines", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 109, no. 36, doi:10.1073/PNAS.1209367109, ISSN 0027-8424, (20120904), pages 14604 - 14609, (20120820), XP002683929
EXAMINATION- MORITZ THRAN ET AL, "mRNA mediates passive vaccination against infectious agents, toxins, and tumors", EMBO MOLECULAR MEDICINE (ONLINE), DE, (20170809), vol. 9, no. 10, doi:10.15252/emmm.201707678, ISSN 1757-4684, pages 1434 - 1447, XP055505303
EXAMINATION- Mamoru Nakanishi ET AL, "New Transfection Agents Based on Liposomes Containing Biosurfactant MEL-A", Pharmaceutics, (20130816), vol. 5, no. 3, doi:10.3390/pharmaceutics5030411, pages 411 - 420, XP055435942
EXAMINATION- Michela Pisani ET AL, "Neutral Liposomes and DNA Transfection", Non-Viral Gene Therapy, InTech, (20111107), doi:10.5772/21283, ISBN 978-953-30-7538-9, XP055771046
INTERNATIONAL-SEARCH-REPORT- GEERTRUI TAVERNIER ET AL, "mRNA as gene therapeutic: How to control protein expression", JOURNAL OF CONTROLLED RELEASE, (20110301), vol. 150, no. 3, doi:10.1016/j.jconrel.2010.10.020, ISSN 0168-3659, pages 238 - 247, XP055068617 [Y] 1-51 * page 242, column r - page 244 *
INTERNATIONAL-SEARCH-REPORT- XINGFANG SU ET AL, "In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles", MOLECULAR PHARMACEUTICS, (20110606), vol. 8, no. 3, doi:10.1021/mp100390w, ISSN 1543-8384, pages 774 - 787, XP055127583 [Y] 1-51 * abstract *
OPPOSITION- CARRASCO et al., "Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration", Commun Biol., (20210000), vol. 4, no. 1, page 956, XP055899421-
OPPOSITION- Charles A Janeway, Paul Travers, Mark Walport And Mark J Shlomchik, "The structure of a typical antibody molecule", Immunobiology, Garland Science, New York, New York , ISBN 978-0-8153-3642-6, (20010101), page 95, Immunobiology, (20180615), XP055484660-
OPPOSITION- DUWURI et al., "Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients", Clin Cancer Res, (20190000), vol. 25, no. 19, pages 5752 - 5758, XP055899544-
OPPOSITION- Fanlei Hu, Wenwei Shao & Xiaoyan Qiu, "Functions and Clinical Relevance of Liver-Derived Immunoglobulins", Non B cell-Derived Immunoglobulins, (20240706), doi:10.1007/978-981-97-0511-5_7, pages 91 - 99-
OPPOSITION- GOLAY et al., "Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics", MAbs, (20130000), vol. 5, no. 6, pages 826 - 37, XP055899418-
OPPOSITION- Handbook of Pharmaceutical Biotechnology-
OPPOSITION- Ji, C. Kaplowitz, N., "ER stress: Can the liver cope?", Journal of Hepatology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20060801), vol. 45, no. 2, ISSN 0168-8278, pages 321 - 333, XP005554454-
OPPOSITION- LEE et al., "BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly", Mol Biol Cell, (19990000), vol. 10, no. 7, pages 2209 - 19, XP008123368-
OPPOSITION- LIN et al., "Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor", The Journal of Pharmacology and Experimental Therapeutics, (19980000), vol. 288, no. 1, pages 371 - 8, XP055899542-
OPPOSITION- "LIPOFECTAMINE 2000 AND LIPOFECTAMINE RNAIMAX TRANSFECTION REAGENTS", Invitrogen, (20130000), XP055899181-
OPPOSITION- MacLachlan I., "Liposomal formulations for nucleic acid delivery", MacLachlan I., CROOKE STANLEY T, ANTISENSE DRUG TECHNOLOGY:PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2ND ED., US , CRC PRESS , (20070101), pages 237 - 270, ISBN 978-0-8493-8796-8, XP002584305-
OPPOSITION- MORI et al., "Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse mode l", Blood Cancer Journal, (20120000), vol. 2, page e67, XP055899736-
OPPOSITION- PASCOLO STEVE, "Messenger RNA-based vaccines.", Expert opinion on biological therapy, Informa Healthcare, UK, UK , (20040801), vol. 4, no. 8, ISSN 1744-7682, pages 1285 - 1294, XP002764729-
OPPOSITION- RAZPOTNIK et al., "Targeting Malignant Brain Tumors with Antibodies", Front Immunol, (20170000), vol. 8, page 1181, XP055899394-
OPPOSITION- SCHLICH et al., "Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles", Bioeng Transl Med., (20210000), vol. 6, no. 2, page e10213, XP055899429-
OPPOSITION- Therapeutic antibody engineering, (20120101), pages 197 - 199, XP055898605-
OPPOSITION- TZABAN et al., "The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity", J. Cell Biol., (20090000), vol. 185, no. 4, pages 673 - 684, XP055899167-
OPPOSITION- Wu H. -Y, Russell M W, "Antibody-secreting cell responses in the mouse liver", Immunology, (19921101), vol. 77, pages 443 - 448, XP093303498-
OPPOSITION- JAYARAMAN et al., "Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo", Angew. Chem. Int. Ed., (20120000), vol. 51, doi:10.1002/anie.201203263, pages 8529 - 8533, XP055063645
OPPOSITION- LEE CHRISTINA J ET AL, "A Clone Screening Method Using mRNA Levels to Determine Specific Productivity and Product Quality for Monoclonal Antibodies", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20090101), vol. 102, no. 4, doi:10.1002/BIT.22126, ISSN 0006-3592, pages 1107 - 1118, XP002525684
OPPOSITION- Yuansheng Yang; Mariati; Steven C.L. Ho; Miranda G.S. Yap, "Mutated polyadenylation signals for controlling expression levels of multiple genes in mammalian cells", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20080929), vol. 102, no. 4, doi:10.1002/bit.22152, ISSN 0006-3592, pages 1152 - 1160, XP071052752
OPPOSITION- MARTINON F., ET AL., "INDUCTION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VIVO BY LIPOSOME-ENTRAPPED MRNA.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930101), vol. 23., doi:10.1002/eji.1830230749, ISSN 0014-2980, pages 1719 - 1722., XP000618955
OPPOSITION- LOBO ED et al., "Antibody pharmacokinetics and pharmacodynamics", J Pharm Sci., (20041100), vol. 93, no. 11, doi:10.1002/jps.20178, pages 2645 - 68, XP002403674
OPPOSITION- XU L et al., "Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics", J Pharm Sci., (20110100), vol. 100, no. 1, doi:10.1002/jps.22243, pages 38 - 52, XP055483026
OPPOSITION- Pascolo Steve, "Vaccination with messenger RNA (mRNA)", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY., SPRINGER VERLAG, BERLIN, DE, BERLIN, DE , (20080101), no. 183, doi:10.1007/978-3-540-72167-3_11, ISSN 0171-2004, pages 221 - 235, XP001538300
OPPOSITION- PASCOLO, "Vaccination with messenger RNA (mRNA", Handbook of Exp. 2008 Pharmacology, vol. 183, doi:10.1007/978-3-540-72167-3_11, pages 221 - 235, XP001538300
OPPOSITION- Healy Sandra Jm, Verfaillie Tom, Jäger Richard, Agostinis Patrizia, Samali Afshin, "Biology of the Endoplasmic Reticulum", Endoplasmic Reticulum Stress in Health and Disease, Springer Netherlands, (20120101), pages 3 - 22, doi:10.1007/978-94-007-4351-9_1, ISBN 978-94-007-4351-9, XP093303505
OPPOSITION- SCHLAKE et al., "mRNA as novel technology for passive immunotherapy", Cell Mol Life Sci., (20180000), vol. 76, doi:10.1007/s00018-018-2935-4, pages 301 - 328, XP036679412
OPPOSITION- Nishimiya Daisuke, "Proteins improving recombinant antibody production in mammalian cells", Applied Microbiology and Biotechnology, Springer Berlin Heidelberg, Berlin/Heidelberg, Berlin/Heidelberg, (20131211), vol. 98, no. 3, doi:10.1007/s00253-013-5427-3, ISSN 0175-7598, pages 1031 - 1042, XP035328534
OPPOSITION- LUTTERBUESE et al., "Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model", Cancer Immunol Immunother, (20070000), vol. 56, no. 4, doi:10.1007/s00262-006-0218-7, pages 459 - 68, XP002428113
OPPOSITION- SANDHU et al., "A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors", Cancer Chemother Pharmacol, (20130000), vol. 71, no. 4, doi:10.1007/s00280-013-2099-8, pages 1041 - 50, XP035339880
OPPOSITION- HAN et al., "Population pharmacokinetics of bevacizumab in cancer patients with external validation", Cancer Chemother Pharmacol, (20160000), vol. 78, doi:10.1007/s00280-016-3079-6, pages 341 - 351, XP036017051
OPPOSITION- Philippot, J. ; Mutaftschiev, S. ; Liautard, J.P., "A very mild method allowing the encapsulation of very high amounts of macromolecules into very large (1000 nm) unilamellar liposomes", Biochimica et Biophysica Acta, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19831012), vol. 734, no. 2, doi:10.1016/0005-2736(83)90111-6, ISSN 0005-2736, pages 137 - 143, XP023359953
OPPOSITION- Roy Jefferis, "Isotype and glycoform selection for antibody therapeutics", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, US , (20121001), vol. 526, no. 2, doi:10.1016/j.abb.2012.03.021, ISSN 0003-9861, pages 159 - 166, XP055292895
OPPOSITION- Ollila, J. Vihinen, M., "B cells", International Journal of Biochemistry and Cell Biology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20050301), vol. 37, no. 3, doi:10.1016/j.biocel.2004.09.007, ISSN 1357-2725, pages 518 - 523, XP004691893
OPPOSITION- Gass, J.N. Jiang, H.Y. Wek, R.C. Brewer, J.W., "The unfolded protein response of B-lymphocytes: PERK-independent development of antibody-secreting cells", Molecular Immunology, PERGAMON, GB, GB , (20071031), vol. 45, no. 4, doi:10.1016/j.molimm.2007.07.029, ISSN 0161-5890, pages 1035 - 1043, XP022322730
OPPOSITION- TJELLE TE et al., "Monoclonal antibodies produced by muscle after plasmid injection and electroporation", Mol Ther., (20040300), vol. 9, no. 3, doi:10.1016/j.ymthe.2003.12.007, pages 328 - 36, XP055415724
OPPOSITION- BAKKER et al., "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", Mol Ther., (20040000), vol. 10, no. 3, doi:10.1016/j.ymthe.2004.06.865, pages 411 - 6, XP004660582
OPPOSITION- SCHLAKE et al., "mRNA: A Novel Avenue to Antibody Therapy?", Mol Ther., (20190000), vol. 27, no. 4, doi:10.1016/j.ymthe.2019.03.002, pages 773 - 784, XP055831379
OPPOSITION- RYBAKOVA et al., "mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Viv o", Molecular Therapy, (20190800), vol. 27, no. 8, doi:10.1016/j.ymthe.2019.05.012, XP055832159
OPPOSITION- SEMPLE et al., "Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures", Biochim Biophys Acta, (20010000), vol. 1510, no. 1-2, doi:10.1016/S0005-2736(00)00343-6, pages 152 - 66, XP004248775
OPPOSITION- SCHLATTER et al., "On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells", Biotechnol Prog., (20050000), vol. 21, no. 1, doi:10.1021/BP049780W, pages 122 - 33, XP008123445
OPPOSITION- KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556
OPPOSITION- Wang Yuhua; Su Hsing-Hao; Yang Yang; Hu Yunxia; Zhang Lu; Blancafort Pilar; Huang Leaf, "Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.", Molecular Therapy, Nature Publishing Group, GB, GB , (20130201), vol. 21, no. 2, doi:10.1038/mt.2012.250, ISSN 1525-0024, pages 358 - 367, XP009170717
OPPOSITION- FANG J, et al, "Stable antibody expression at therapeutic levels using the 2A peptide.", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20050417), vol. 23, no. 5, doi:10.1038/nbt1087, ISSN 1087-0156, pages 584 - 590, XP002369310
OPPOSITION- Norbert Pardi, Anthony J. Secreto, Xiaochuan Shan, Fotini Debonera, Joshua Glover, Yanjie Yi, Hiromi Muramatsu, Houping Ni, Barbara L. Mui, Ying K. Tam, Farida Shaheen, Ronald G. Collman, Katalin Karikó, Gwenn A. Danet-Desnoyers, Thomas D. Madden, Michael J. Hope, Drew Weissman, "Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge", Nature Communications, vol. 8, doi:10.1038/ncomms14630, page 14630, XP055557652
OPPOSITION- AKINC et al., "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs", Nat Nanotechnol., (20190000), vol. 14, no. 12, doi:10.1038/s41565-019-0591-y, pages 1084 - 1087, XP036953174
OPPOSITION- PROBST et al., "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent", Gene Ther, (20070000), vol. 14, no. 15, doi:10.1038/SJ.GT.3302964, pages 1175 - 80, XP002679377
OPPOSITION- HILLMEN et al., "The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria", N Engl J Med., (20060000), vol. 355, doi:10.1056/NEJMoa061648, pages 1233 - 1243, XP002482088
OPPOSITION- Ballow Mark, "Primary immunodeficiency disorders: Antibody deficiency", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20020401), vol. 109, no. 4, doi:10.1067/mai.2002.122466, ISSN 0091-6749, pages 581 - 591, XP093303501
OPPOSITION- K. T. Love, K. P. Mahon, C. G. Levins, K. A. Whitehead, W. Querbes, J. R. Dorkin, J. Qin, W. Cantley, L. L. Qin, T. Racie, M. Frank-Kamenetsky, K. N. Yip, R. Alvarez, D. W. Y. Sah, A. De Fougerolles, K. Fitzgerald, V. Koteliansky, A. Akinc, R. Langer, D. G. Anderson, "Lipid-like materials for low-dose, in vivo gene silencing", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20100202), vol. 107, no. 5, doi:10.1073/pnas.0910603106, ISSN 00278424, pages 1864 - 1869, XP055077922
OPPOSITION- Andrew J. Geall, Ayush Verma, Gillis R. Otten, Christine A. Shaw, Armin Hekele, Kaustuv Banerjee, Yen Cu, Clayton W. Beard, Luis A. Brito, Thomas Krucker, Derek T. O�Hagan, Manmohan Singh, Peter W. Mason, Nicholas M. Valiante, Philip R. Dormitzer, Susan W. Barnett, Rino Rappuoli, Jeffrey B. Ulmer, Christian W. Mandl, "Nonviral delivery of self-amplifying RNA vaccines.", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20120904), vol. 109, no. 36, doi:10.1073/PNAS.1209367109, ISSN 0027-8424, pages 14604 - 14609, XP002683929
OPPOSITION- GEALL et al., "Nonviral delivery of self-amplifying RNA vaccines", PNAS, (20120000), vol. 109, no. 36, pages 14604 - 14609, XP002683929
OPPOSITION- DORAI et al., "Correlation of heavy and light chain mRNA copy numbers to antibody productivity in mouse myeloma production cell lines", Hybridoma, (20060000), vol. 25, no. 1, doi:10.1089/hyb.2006.25.1, pages 1 - 9, XP008116842
OPPOSITION- KULKARNI et al., "Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility", Nucleic Acid Ther., (20180000), vol. 28, no. 3, doi:10.1089/nat.2018.0721, pages 146 - 157, XP055551908
OPPOSITION- Moore Kristin A., Hollien Julie, "The Unfolded Protein Response in Secretory Cell Function", ANNUAL REVIEW OF GENETICS., ANNUAL REVIEWS INC., PALO ALTO, CA, US, US , (20121215), vol. 46, no. 1, doi:10.1146/annurev-genet-110711-155644, ISSN 0066-4197, pages 165 - 183, XP093303508
OPPOSITION- JIANG et al., "Gene therapy using adenovirus-mediated full-length anti- HER-2 antibody for HER-2 overexpression cancers", Clin Cancer Res., (20060000), vol. 12, doi:10.1158/1078-0432.CCR-06-0746, pages 6179 - 85, XP055167239
OPPOSITION- Lien Van Hoecke, Roose Kenny, "How mRNA therapeutics are entering the monoclonal antibody field", Journal of Translational Medicine, vol. 17, no. 1, doi:10.1186/s12967-019-1804-8, XP055611427
OPPOSITION- Kirk Semra J, Cliff Jacqueline M, Thomas J Alero, Ward Theresa H, "Biogenesis of secretory organelles during B cell differentiation", Journal of Leukocyte Biology, Society for Leukocyte Biology, US, US , (20091104), vol. 87, no. 2, doi:10.1189/jlb.1208774, ISSN 0741-5400, pages 245 - 255, XP093303506
OPPOSITION- MACLACHLAN, "Liposomal Formulations for Nucleic Acid Delivery", Antisense Drug Technology, (20070000), doi:10.1201/9780849387951.ch9, ISBN 0-8493-8796-5, pages 237 - 270, XP055591157
OPPOSITION- Pascolo S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, Humana Press, (20060101), ISSN 1543-1894, pages 23 - 40, XP009117840
OPPOSITION- THRAN et al., "mRNA mediates passive vaccination against infectious agents, toxins, and tumors", EMBO Molecular Medicine, (20170809), XP055505303
OPPOSITION- SCHLAKE et al., "Developing mRNA-vaccine technologies", RNA Biol., (20120000), vol. 9, no. 11, doi:10.4161/rna.22269, pages 1319 - 30, XP055561756
OPPOSITION- Michela Pisani, Giovanna Mobbili, Paolo Bruni, "Neutral Liposomes and DNA Transfection", Non-Viral Gene Therapy, InTech , (20111107), doi:10.5772/21283, ISBN 978-953-30-7538-9, XP055771048
OTHER- NAKANASHI et al., "New Transfection Agents Based on Liposomes ContainingBiosurfactant MEL-A", Pharmaceuticals, (20130816), vol. 5, no. 3, pages 411 - 420, XP0055435942-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents